Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > La Presse article
View:
Comment by MrMugsy on Jan 18, 2022 12:18pm
Good little chat - more of a review of where we've been. Most recent numbers came from Samira - 700 employees in LATAM and 40 in Canada. Roughtly 740 employees in early January 2022. Let's see what happens to that number by yearend.
Comment by gudisgood on Jan 18, 2022 1:11pm
Thanks for the link. Nice to see Samira interviewed even though it would have been even nicer to get a longer / more in-depth interview. I wonder if this is translated correctly: Q. I noticed that some company insiders, including the founder, Jonathan Goodman, and you, have made several purchases of stock lots recently. Is Knight Therapeutics' share price an issue for you? A. Yes ...more  
Comment by EbbFlow88 on Jan 18, 2022 1:30pm
I was interested in that Q&A section also. I understand it that it's more of a disappointment as in the following paragraph she continues that the stock was higher when they had just cash and nothing else to show. In the last year, ending septebmer 30th they have 240M in revenues and 40M in cash flow, increasing results in last three quarters and the Exelon acquisition and the market is ...more  
Comment by MrMugsy on Jan 18, 2022 1:38pm
Yes - but she knows better than anyone how to wait for the market to swing in her favour. She has never tried to force the market to love you. Waiting is hard but if you have thick skin - no problem - the market alwasy comes around if there's real growth. And - Samira has thick skin.  Ever seen her handle Goodman?  She's good.
Comment by Chianchin on Jan 18, 2022 2:33pm
Warning!!!! EBflow and mugsy is the same person. 
Comment by MrMugsy on Jan 18, 2022 1:33pm
Exactly - they have a plan. Excessive share price - go to market. Low share price - buyback. All the while - grow the business while taking little risk in the process. Now we know ... ROW is a superconductor for the future. Partnering with small pharma developers are lottary tickets they pretty well get for free but represent huge opportunity should one hit. Collect enough lottary tickets and you ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities